Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|April 4, 2023

Discussing Soft Mist Inhaler Technology with Marcel Baumann (World Vaccine Conference 2023)

Author(s)Chris Spivey

Marcel Baumann, business development director at Recipharm, discusses soft mist inhaler technology from the show floor at the World Vaccine Conference.

Marcel Baumann, business development director at Recipharm, discusses soft mist inhaler technology from the show floor at the World Vaccine Conference.


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.